Tomas Robyns1,2, Hua Rong Lu3, David J Gallacher3, Christophe Garweg1,2, Joris Ector1,2, Rik Willems1,2, Stefan Janssens1,2, Dieter Nuyens1,2. 1. Department of Cardiovascular Diseases, University Hospitals, Leuven, Belgium. 2. Department of Cardiovascular Sciences, University of Leuven, Belgium. 3. Global Safety Pharmacology, Discovery Sciences, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium.
Abstract
BACKGROUND: Recently a new risk marker for drug-induced arrhythmias called index of cardio-electrophysiological balance (iCEB), measured as QT interval divided by QRS duration, was evaluated in an animal model. It was hypothesized that iCEB is equivalent to the cardiac wavelength λ (λ = effective refractory period (ERP) x conduction velocity) and that an increased or decreased value of iCEB would potentially predict an increased susceptibility to TdP or non-TdP mediated VT/VF, respectively. METHODS: First, the correlation between QT interval and ERP was evaluated by invasively measuring ERP during a ventricular stimulation protocol in humans (N = 40). Then the effect of administration of sotalol and flecainide on iCEB was measured in 40 patients with supraventricular tachycardias. Finally iCEB was assessed in carriers of a long QT syndrome (LQTS, N = 70) or Brugada syndrome (BrS, N = 57) mutation and compared them with genotype negative family members (N = 65). RESULTS: The correlation between QT interval and ERP was established (Pearson R(2) = 0.25) which suggests that iCEB≈ERPxCV≈QT/QRS. Sotalol administration increased iCEB (+ 0.23; P = 0.01), while it decreased with the administration of flecainide (-0.21, P = 0.03). In the LQTS group iCEB was increased (5.22 ± 0.93, P < 0.0001) compared to genotype negative family members (4.24 ± 0.5), while it was decreased in the BrS group (3.52 ± 0.43, P < 0.0001). CONCLUSIONS: Our data suggest that iCEB (QT/QRS) is a simple but effective ECG surrogate of cardiac wavelength. iCEB is increased in situations that predispose to TdP and is decreased in situations that predispose to non-TdP mediated VT/VF. Therefore, iCEB might serve as a noninvasive and readily measurable marker to detect increased arrhythmic risk.
BACKGROUND: Recently a new risk marker for drug-induced arrhythmias called index of cardio-electrophysiological balance (iCEB), measured as QT interval divided by QRS duration, was evaluated in an animal model. It was hypothesized that iCEB is equivalent to the cardiac wavelength λ (λ = effective refractory period (ERP) x conduction velocity) and that an increased or decreased value of iCEB would potentially predict an increased susceptibility to TdP or non-TdP mediated VT/VF, respectively. METHODS: First, the correlation between QT interval and ERP was evaluated by invasively measuring ERP during a ventricular stimulation protocol in humans (N = 40). Then the effect of administration of sotalol and flecainide on iCEB was measured in 40 patients with supraventricular tachycardias. Finally iCEB was assessed in carriers of a long QT syndrome (LQTS, N = 70) or Brugada syndrome (BrS, N = 57) mutation and compared them with genotype negative family members (N = 65). RESULTS: The correlation between QT interval and ERP was established (Pearson R(2) = 0.25) which suggests that iCEB≈ERPxCV≈QT/QRS. Sotalol administration increased iCEB (+ 0.23; P = 0.01), while it decreased with the administration of flecainide (-0.21, P = 0.03). In the LQTS group iCEB was increased (5.22 ± 0.93, P < 0.0001) compared to genotype negative family members (4.24 ± 0.5), while it was decreased in the BrS group (3.52 ± 0.43, P < 0.0001). CONCLUSIONS: Our data suggest that iCEB (QT/QRS) is a simple but effective ECG surrogate of cardiac wavelength. iCEB is increased in situations that predispose to TdP and is decreased in situations that predispose to non-TdP mediated VT/VF. Therefore, iCEB might serve as a noninvasive and readily measurable marker to detect increased arrhythmic risk.
Authors: Silvia G Priori; Arthur A Wilde; Minoru Horie; Yongkeun Cho; Elijah R Behr; Charles Berul; Nico Blom; Josep Brugada; Chern-En Chiang; Heikki Huikuri; Prince Kannankeril; Andrew Krahn; Antoine Leenhardt; Arthur Moss; Peter J Schwartz; Wataru Shimizu; Gordon Tomaselli; Cynthia Tracy; Michael Ackerman; Bernard Belhassen; N A Mark Estes; Diane Fatkin; Jonathan Kalman; Elizabeth Kaufman; Paulus Kirchhof; Eric Schulze-Bahr; Christian Wolpert; Jitendra Vohra; Marwan Refaat; Susan P Etheridge; Robert M Campbell; Edward T Martin; Swee Chye Quek Journal: Europace Date: 2013-08-30 Impact factor: 5.214
Authors: Jorgen K Kanters; Christian Haarmark; Esben Vedel-Larsen; Mads P Andersen; Claus Graff; Johannes J Struijk; Poul Erik Bloch Thomsen; Michael Christiansen; Henrik K Jensen; Egon Toft Journal: J Electrocardiol Date: 2008-09-25 Impact factor: 1.438
Authors: Samuel Horr; Ilan Goldenberg; Arthur J Moss; Jin O-Uchi; Alon Barsheshet; Heather Connelly; Daniel A Gray; Wojciech Zareba; Coeli M B Lopes Journal: J Cardiovasc Electrophysiol Date: 2011-02
Authors: Jan Nemec; Marie Buncová; Veronika Bůlková; Joseph Hejlik; Bruce Winter; Win-Kuang Shen; Michael J Ackerman Journal: J Cardiovasc Electrophysiol Date: 2004-05
Authors: Gary Tse; Tong Liu; Ka H C Li; Victoria Laxton; Yin W F Chan; Wendy Keung; Ronald A Li; Bryan P Yan Journal: Front Physiol Date: 2016-10-18 Impact factor: 4.566
Authors: Sebastian Polak; Klaus Romero; Alexander Berg; Nikunjkumar Patel; Masoud Jamei; David Hermann; Debra Hanna Journal: J Pharmacokinet Pharmacodyn Date: 2018-03-08 Impact factor: 2.745
Authors: Gary Tse; Ka Hou Christien Li; Guangping Li; Tong Liu; George Bazoukis; Wing Tak Wong; Matthew T V Chan; Martin C S Wong; Yunlong Xia; Konstantinos P Letsas; Gary Chin Pang Chan; Yat Sun Chan; William K K Wu Journal: Front Cardiovasc Med Date: 2018-10-04